Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 144 No. 0910 (2014)

Propranolol in infantile haemangioma: simplifying pretreatment monitoring

  • Oumama El Ezzi
  • Judith Hohlfeld
  • anthony de Buys Roessingh
DOI
https://doi.org/10.4414/smw.2014.13943
Cite this as:
Swiss Med Wkly. 2014;144:w13943
Published
23.02.2014

Summary

BACKGROUND: Infantile haemangiomas (IHs) are very common vascular tumours. Propranolol is at present the first-line treatment for problematic and complicated haemangioma. In accordance with a Swiss protocol, children are monitored for 2 days at the start of the treatment to detect possible side effects of this drug. Our study advocates a simplification of the pretreatment monitoring process.

METHODS: All children with a problematic and complicated haemangioma treated with propranolol between September 2009 and September 2012 were included in the study. All patients were hospitalised under constant nurse supervision for 48 hours at the start of the treatment and subjected to cardiac and blood measurements. The dosage of propranolol was 1 mg/kg/day on the first day and 2 mg/kg/day from the second day. Demographic data, clinical features, treatment outcome and complications were analysed.

RESULTS: Twenty-nine infants were included in our study. Of these, 86.2% responded immediately to the treatment. There were no severe adverse reactions. Six patients presented transient side effects such as bradycardia, hypotension after the first dose and hypoglycaemia later. No side effects occurred after the second dose. Treatment was never interrupted.

CONCLUSION: Propranolol (a β-blocker) is a safe treatment for problematic IH. Side effects may occur after the first dose. A strict 48 hour monitoring in hospital is expensive and may be unnecessary as long as the contraindications for the drug are respected.

References

  1. Mulliken JB, Glowacki J. Hemangioma and vascular malformations in infants and children: A classification based on endothelial characteristics. Plast Reconstr surg. 1982;69:412–22.
  2. Amir J, Metzker A, Krickler R, Reisner SH. Strawberry haemangioma in preterm infants. Pediatr Dermatol. 1986;3:331–2.
  3. Boon L, Enjolras O, Mulliken JB. Congenital haemangioma: evidence of accelerated involution. J Pediatr. 1996;128:329–35.
  4. Frieden IJ, Reese V, Cohen D. PHACE syndrome: The association of posterior fossa brain malformations, haemangioma, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol. 1996;132:307–11.
  5. Drolet BA, Esterly NB, Frieden IJ. Hemangioma in children. N Engl J Med. 1999;341:173–81.
  6. Theletsane T, Redfern A, Raynham O, and al. Life threatening haemangioma: a dramatic response to propranolol. J Eur Acad Dermatol Venereol. 2009;23:1465–6.
  7. Léauté-Labrèze C, Dumas de la Roque E, et al. Propranolol for severe haemangioma of infancy. N Engl J Med. 2008;358:2649–51.
  8. Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells in Vitro. Cell Dev Biol Anim. 2002;38:298–304.
  9. Sánchez-Carpintero I, Ruiz-Rodriguez R, López-Gutiérrez JC. Propranolol in the treatment of infantile haemangioma: clinical effectiveness, risks, and recommendations. Actas Dermosifiliogr. 2011;102:766–79.
  10. Initiation and Use of Propranolol for Infantile Hemangioma: Report of a Consensus Conference. Pediatrics. 2013;131;1691.
  11. Tan ST, Itinteang T, Leadbitter P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg. 2011;64:292–9.
  12. Graaf M, Breur MJ, Raphae MF, et al. Adverse effects of propranolol when used in the treatment of haemangioma: a case series of 28 infants. J Am Acad Dermatol. 2011;65:320–7.
  13. Lisa Weibel, Swiss Grand Round for Vascular Anomalies in Childhood und Swiss Group for Paediatric Dermatology. Propranolol-un nouveau traitement pour les hémangiomes infantiles. Forum Med Suisse. 2009;9:573.
  14. Chang J, Most D, Bresnick S, et al. Proliferative haemangioma: analysis of cytokines gene expression and angiogenesis. Plast reconstr surg. 1999;103:1.
  15. Marler J, Mulliken J. Current management of haemangioma and vascular malformations. Clin Plastic Surg. 2005;32:99–116.
  16. Greinwald JH, Burke DK, Bonthius DJ, et al. An update on the treatment of haemangioma in children with interferon alpha-2a. Arch otolaryngol head Neck Surg. 1999;125:21.
  17. Denoyelle F, Leboulanger N, Enjolras O, et al. Role of propranolol in the therapeutic strategy of infantile laryngotreacheal haemangioma. Internat J Ped Othorhinol. 2009;73:1168–72.
  18. Manunza F, Syed S, Laguda B, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol. 2010;162:466–8.
  19. Betlloch-Mas I, Martínez-Miravete MT, Lucas-Costa A, et al. Outpatient Treatment of Infantile Haemangioma With Propranolol: A Prospective Study. Actas Dermosifiliogr. 2012;103:806–15.
  20. Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg. 2011;64:445–51.
  21. Teng-Chin Hsu, Jiaan-Der Wang, Chao-Huei Chen, et al. Treatment With Propranolol for Infantile Hemangioma in 13 Taiwanese Newborns and Young Infants. Pediatrics and Neonatology. 2012;53:125–32.

Most read articles by the same author(s)